Last Update: Aug 10, 2026 Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients ClinicalTrials.gov Identifier: [NCT07142265](https://clinicaltrials.gov/ct2/show/NCT07142265) Novartis Reference Number:CKJX839D1RU01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI/non-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up. Condition Myocardial Infarction Overall Status Recruiting Number of Participants300 Start Date Sep 30, 2025 Completion Date Sep 30, 2027 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion Criteria: \* Adult patients of both genders \* Myocardial Infarction diagnosis \* Dyslipidemia diagnosis \* The first injection of inclisiran no later than 14 ± 5 days after the STEMI/non-STEMI \* LDL-C \\> 5 mmol/L (statin-naive patients) or LDL-C \\> 2.5 mmol/L (on the basis of statin MTD) at the time of hospitalization or no target LDL-C level (\\> 1.4 mmol/L or no LDL-C level decrease by 50% on statin MTD + ezetimibe) \* Signed Informed Consent Form (ICF) Exclusion Criteria: \* Severe oncological and somatic diseases with system and organ failure\\\* \* Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection) \* History of therapy with PCSK9 inhibitors \* Active inflammatory liver disease or the levels of AST, ALT \\> 3 times, or total bilirubin \\> 2 times higher than the upper limit of norm \* Any other MACE in the anamnesis Russia #### Novartis Investigative Site Recruiting Penza,440026,Russia #### Novartis Investigative Site Recruiting Orenburg,460018,Russia #### Novartis Investigative Site Recruiting Kaluga,248000,Russia #### Novartis Investigative Site Recruiting Samara,443070,Russia #### Novartis Investigative Site Recruiting Moscow,121552,Russia #### Novartis Investigative Site Recruiting Khanty-Mansiysk,628012,Russia #### Novartis Investigative Site Recruiting Tomsk,634009,Russia #### Novartis Investigative Site Recruiting Syktyvkar,167981,Russia #### Novartis Investigative Site Recruiting S Petersburg,192242,Russia #### Novartis Investigative Site Recruiting Petrozavodsk,185019,Russia #### Novartis Investigative Site Recruiting Moscow,119607,Russia #### Novartis Investigative Site Recruiting Grozny,364051,Russia #### Novartis Investigative Site Recruiting Ulan-Ude,670031,Russia #### Novartis Investigative Site Recruiting Rostov-on-Don,344010,Russia #### Novartis Investigative Site Recruiting Novosibirsk,630051,Russia #### Novartis Investigative Site Recruiting Moscow,105203,Russia #### Novartis Investigative Site Recruiting Kemerovo,650002,Russia #### Novartis Investigative Site Recruiting Cheboksary,428000,Russia ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: